Mechanisms of defense against intracellular pathogens mediated by human macrophages

Microbiology Spectrum

Volumn 4, Issue 3, 2016, Pages

  Bloom, Barry R ^a   Modlin, Robert L ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; DISEASE RESISTANCE; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; MACROPHAGE; MICROBIOLOGY; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; DISEASE RESISTANCE; HOST-PATHOGEN INTERACTIONS; HUMANS; MACROPHAGES; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 85008444844     PISSN: None     EISSN: 21650497     Source Type: Journal    
DOI: 10.1128/microbiolspec.MCHD-0006-2015     Document Type: Article

References (59)

1. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. 1993. An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249-2254.
2. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR. 1995. Tumor necrosis factor-a is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572.
3. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. 1992. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 89:12013-12017.
4. Dunn PL, North RJ. 1991. Resolution of primary murine listeriosis and acquired resistance to lethal secondary infection can be mediated predominantly by Thy-1+ CD4-CD8-cells. J Infect Dis 164:869-877.
5. Turner J, D'Souza CD, Pearl JE, Marietta P, Noel M, Frank AA, Appelberg R, Orme IM, Cooper AM. 2001. CD8-and CD95/95Ldependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am J Respir Cell Mol Biol 24:203-209.
6. Chan J, Fan XD, Hunter SW, Brennan PJ, Bloom BR. 1991. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 59:1755-1761.
7. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 63:736-740.
8. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 94:5243-5248.
9. Bryk R, Lima CD, Erdjument-Bromage H, Tempst P, Nathan C. 2002. Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science 295:1073-1077.
10. Chan J, Xing Y, Magliozzo RS, Bloom BR. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 175:1111-1122.
11. Chan J, Fujiwara T, Brennan P, McNeil M, Turco SJ, Sibille JC, Snapper M, Aisen P, Bloom BR. 1989. Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. Proc Natl Acad Sci U S A 86:2453-2457.
12. Darwin KH, Ehrt S, Gutierrez-Ramos JC, Weich N, Nathan CF. 2003. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302:1963-1966.
13. Modlin RL, Melancon-Kaplan J, Young SM, Pirmez C, Kino H, Convit J, Rea TH, Bloom BR. 1988. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci U S A 85:1213-1217.
14. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL. 1991. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277-279.
15. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279-282.
16. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. 1986. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357.
17. Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, Barnes PF, Rollinghoff M, Bolcskei PL, Wagner M, Akira S, Norgard MV, Belisle JT, Godowski PJ, Bloom BR, Modlin RL. 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291:1544-1547.
18. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-1773.
19. Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M, Wheelwright M, Vazirnia A, Zhang X, Steinmeyer A, Zügel U, Hollis BW, Cheng G, Modlin RL. 2009. Convergence of IL-1β and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 4:e5810. doi:10.1371/journal.pone.0005810.
20. Liu PT, Stenger S, TangDH, Modlin RL. 2007. Cutting edge: vitamin Dmediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 179:2060-2063.
21. Douvas GS, Looker DL, Vatter AE, Crowle AJ. 1985. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun 50:1-8.
22. 3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57:159-163.
23. 3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 62:229-234.
24. Denis M. 1991. Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitriol. Clin Exp Immunol 84:200-206.
25. Robertson AK, Andrew PW. 1991. Interferon gamma fails to activate human monocyte-derived macrophages to kill or inhibit the replication of a non-pathogenic mycobacterial species. Microb Pathog 11:283-288.
26. Olakanmi O, Britigan BE, Schlesinger LS. 2000. Gallium disrupts iron metabolism of mycobacteria residing within human macrophages. Infect Immun 68:5619-5627.
27. Bonecini-Almeida MG, Chitale S, Boutsikakis I, Geng J, Doo H, He S, Ho JL. 1998. Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-γ and primed lymphocytes. J Immunol 160:4490-4499.
28. Kumar D, Nath L, Kamal MA, Varshney A, Jain A, Singh S, Rao KV. 2010. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140:731-743.
29. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, Lee HM, Krutzik SR, Schenk M, Sieling PA, Teles R, Montoya D, Iyer SS, Bruns H, Lewinsohn DM, Hollis BW, Hewison M, Adams JS, Steinmeyer A, Zügel U, Cheng GH, Jo EK, Bloom BR, Modlin RL. 2011. Vitamin D is required for IFN-γ-mediated antimicrobial activity of human macrophages. Sci Transl Med 3:104ra102. doi:10.1126/scitranslmed.3003045.
30. 3. FASEB J 19:1067-1077.
31. 3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173:2909-2912.
32. Green M. 2011. Cod liver oil and tuberculosis. BMJ 343:d7505. doi:10.1136/bmj.d7505.
33. Stead WW, Senner JW, Reddick WT, Lofgren JP. 1990. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 322:422-427.
34. Rich AR. 1944. Pathogenesis of Tuberculosis. Charles C Thomas, Publisher, Springfield, IL.
35. Martineau AR, Nhamoyebonde S, Oni T, Rangaka MX, Marais S, Bangani N, Tsekela R, Bashe L, de Azevedo V, Caldwell J, Venton TR, Timms PM, Wilkinson KA, Wilson RJ. 2011. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 108:19013-19017.
36. Morcos MM, Gabr AA, Samuel S, Kamel M, el Baz M, el Beshry M, Michail RR. 1998. Vitamin D administration to tuberculous children and its value. Boll Chim Farm 137:157-164.
37. Nursyam EW, Amin Z, Rumende CM. 2006. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones 38:3-5.
38. Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F. 2013. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis]. BMC Infect Dis 13:22. doi:10.1186/1471-2334-13-22.
39. 3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377:242-250.
40. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR, Bothamley GH, Packe GE, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Mein CA, Bhaw-Rosun L, Nuamah R, Young DB, Drobniewski FA, Griffiths CJ, Martineau AR. 2012. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 109:15449-15454.
41. Ganmaa D, Giovannucci E, Bloom BR, Fawzi W, Burr W, Batbaatar D, Sumberzul N, Holick MF, Willett WC. 2012. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial. Am J Clin Nutr 96:391-396.
42. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. 2010. An interferoninducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466:973-977.
43. Maertzdorf J, Weiner J III, Mollenkopf HJ, TBornotTB Network, Bauer T, Prasse A, Müller-Quernheim J, Kaufmann SH. 2012. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 109:7853-7858.
44. Ottenhoff TH, Dass RH, Yang N, Zhang MM, Wong HE, Sahiratmadja E, Khor CC, Alisjahbana B, van Crevel R, Marzuki S, Seielstad M, van de Vosse E, Hibberd ML. 2012. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One 7:e45839. doi:10.1371/journal.pone.0045839.
45. Bloom CI, Graham CM, Berry MP, Wilkinson KA, Oni T, Rozakeas F, Xu Z, Rossello-Urgell J, Chaussabel D, Banchereau J, Pascual V, Lipman M, Wilkinson RJ, O'Garra A. 2012. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 7:e46191. doi:10.1371/journal.pone.0046191.
46. Stanley SA, Johndrow JE, Manzanillo P, Cox JS. 2007. The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol 178:3143-3152.
47. Manzanillo PS, Shiloh MU, Portnoy DA, Cox JS. 2012. Mycobacterium tuberculosis activates the DNA-dependent cytosolic surveillance pathway within macrophages. Cell Host Microbe 11:469-480.
48. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE III, Freedman VH, Kaplan G. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β. Proc Natl Acad Sci U S A 98:5752-5757.
49. Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, Murray PJ, Barry C, Kaplan G. 2005. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 25:694-701.
50. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, Komisopoulou E, Kelly-Scumpia K, Chun R, Iyer SS, Sarno EN, Rea TH, Hewison M, Adams JS, Popper SJ, Relman DA, Stenger S, Bloom BR, Cheng G, Modlin RL. 2013. Type I interferon suppresses type II interferontriggered human anti-mycobacterial responses. Science 339:1448-1453.
51. Anonymous. 1999. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res 110:56-69.
52. + T cells. Eur J Immunol 40:279-290.
53. Matsumiya M, Stylianou E, Griffiths K, Lang Z, Meyer J, Harris SA, Rowland R, Minassian AM, Pathan AA, Fletcher H, McShane H. 2013. Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. PLoS One 8:e67922. doi:10.1371/journal.pone.0067922.
54. Kaforou M, Wright VJ, Oni T, French N, Anderson ST, Bangani N, Banwell CM, Brent AJ, Crampin AC, Dockrell HM, Eley B, Heyderman RS, Hibberd ML, Kern F, Langford PR, Ling L, Mendelson M, Ottenhoff TH, Zgambo F, Wilkinson RJ, Coin LJ, Levin M. 2013. Detection of tuberculosis in HIV-infected and-uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med 10: e1001538. doi:10.1371/journal.pmed.1001538.
55. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, Mahomed H, Hawkridge A, Hussey G, Kaplan G, Hanekom WA. 2010. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 182:1073-1079.
56. Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RM, Vaidya P, Munoz MA, Schenk M, Swindell WR, Chun R, Zavala K, Hewison M, Adams JS, Horvath S, Pellegrini M, Bloom BR, Modlin RL. 2014. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med 6:250ra114. doi:10.1126/scitranslmed.3009546.
57. Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D, Meng X, Chan ED, Yoon DY, Ottenhoff T, Kim SH, Dinarello CA. 2006. Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-γ-dependent mechanism. PLoS Med 3:e277. doi:10.1371/journal.pmed.0030277.
58. Schenk M, Krutzik SR, Sieling PA, Lee DJ, Teles RM, Ochoa MT, Komisopoulou E, Sarno EN, Rea TH, Graeber TG, Kim S, Cheng G, Modlin RL. 2012. NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med 18:555-563.
59. Barksby HE, Nile CJ, Jaedicke KM, Taylor JJ, Preshaw PM. 2009. Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide. Clin Exp Immunol 156:479-487.